• Active Surveillance Safe for Black Men With Low-risk Diagnosis, Study Finds
  • Nubeqa Prescribing Information Updated With New Survival Data
  • Orgovyx Now Available in US for Advanced Prostate Cancer
  • Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients
  • Long-term ADT Found to Raise Risk of Cardiovascular Death
  • FDA Approves Orgovyx, Oral ADT for Advanced Prostate Cancer
  • Teams Working in Advanced Cancer Win 2020 PCF Challenge Awards
  • Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells
  • Canada Approves Lynparza for Metastatic CRPC Patients With Certain Gene Mutations
  • FDA Puts RV001 on Fast Track for Treating Prostate Cancer
  • FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer
  • FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients